1️⃣ Coultreon just made SIK3 financeable
Coultreon said on April 28 that it closed an oversubscribed $125M Series A led by Sofinnova, with Forbion and Novo Holdings co-leading, to take oral SIK3 inhibitor COL-5671 from phase 1 into phase 2 in psoriasis and ulcerative colitis.
💡 Why it matters
This is not seed noise. A discarded Galapagos asset just pulled a serious syndicate because investors think oral immunology still has room if the biology is cleaner than another cytokine clone.
☕ Coffee talk
If a recycled asset can raise $125M on mechanism and setup, what does that say about how thin the next oral immunology bench really is?
2️⃣ Survodutide kept Boehringer in the obesity race
Boehringer said on April 28 that phase 3 SYNCHRONIZE-1 met both co-primary endpoints: adults without type 2 diabetes lost up to 16.6% of body weight at 76 weeks versus 3.2% on placebo, and 85.1% got to at least 5% weight loss.
💡 Why it matters
This does not reset the obesity leaderboard. It does keep survodutide investable because the glucagon angle and the liver readthrough could matter more than winning the headline percentage by a few points.
☕ Coffee talk
If the same asset can sell an obesity case and a MASH case, who still gets valued on one lane only?
3️⃣ Otarmeni made inner-ear gene therapy real
The FDA approved Otarmeni on April 23 for OTOF-related severe-to-profound hearing loss, making it the first dual-AAV gene therapy and doing it 61 days after BLA filing under the national priority voucher program.
💡 Why it matters
This is more than a rare-disease approval. It shows a technically awkward gene therapy can get through fast when the effect is clear, which changes the bar for other sensory and localized delivery programs.
☕ Coffee talk
A dual-vector cochlear gene therapy got through in 61 days. Which programs still get to hide behind “too complex to approve”?